Actively Recruiting
Open-Label Study Evaluating Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Adults with Systemic Sclerosis
Led by Cabaletta Bio · Updated on 2026-10-16
37
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
The trial investigates systemic sclerosis SSc, a rare autoimmune disorder characterized by abnormal B cell function and tissue fibrosis affecting skin and organs. Researchers are evaluating an investigational therapy called CABA-201, a CD19-CAR T cell therapy, to assess its safety and efficacy in patients with active systemic sclerosis. The study includes participants with significant skin, lung, or heart involvement and aims to understand how this therapy may impact these symptoms. Participants will receive a single intravenous infusion of CABA-201 after preconditioning treatment with cyclophosphamide and fludarabine. The study has two groups one with severe skin involvement and another with organ involvement. Both groups receive the investigational therapy with the same preconditioning regimen. This is an open-label, non-randomized study spanning Phase 12 and Phase 2b sub-study periods. During the trial, participants will be monitored closely for adverse events up to 28 days after infusion and for efficacy outcomes such as lung function and skin score over a year and beyond. Assessments include laboratory tests, safety evaluations, and measurements of lung capacity and skin thickness. Follow-up extends up to 156 weeks to evaluate long-term effects. The total duration involves regular visits and detailed tracking of participants health and response to the therapy.
CONDITIONS
Brief Title
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Research Team
C
Cabaletta Bio
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here